Skip to main content

Advertisement

Fig. 3 | EJNMMI Research

Fig. 3

From: Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples

Fig. 3

a 111In-RM2 binding in low-, intermediate-, and high-risk prostate cancer samples. 111In-RM2 binding is significantly higher in low metastatic risk compared to intermediate- or high-risk samples. b 111In-PSMA-617 binding in low-, intermediate-, and high-risk prostate cancer samples. Binding of 111In-PSMA-617 is high in all samples with no significant differences between groups. Non-parametric one-way ANOVA (Kruskal-Wallis test). p < 0.05 was considered significant

Back to article page